Recent clinical trials have demonstrated the significant efficacy of pembrolizumab (PD-1 inhibitor) and ipilimumab (CTLA4 inhibitor) in anti-tumour activity, bringing in a new dawn in CCA treatment [42]. The gene discussed is CTLA4; the disease is cholangiocarcinoma.